Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver

被引:8
作者
Huibers, Anne [1 ,2 ]
Depalo, Danielle K. [3 ]
Perez, Matthew C. [3 ]
Zager, Jonathan S. [3 ,4 ]
Olofsson Bagge, Roger [1 ,2 ]
机构
[1] Sahlgrens Univ Hosp, Dept Radiol, S-41345 Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci Obstet & Gynecol, S-41390 Gothenburg, Sweden
[3] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[4] Univ South Florida Hlth, Morsani Coll Med, Dept Oncol Sci, Tampa, FL USA
关键词
In transit metastasis; Uveal melanoma; Isolated limb perfusion; Isolated limb infusion; Isolated hepatic perfusion; Percutaneous hepatic perfusion; TERM-FOLLOW-UP; MALIGNANT-MELANOMA; OCULAR MELANOMA; CHOROIDAL MELANOMA; INFUSION; CHEMOTHERAPY; PROGRESSION; MELPHALAN; CANCER; PROGNOSIS;
D O I
10.1007/s10585-023-10234-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Patients with cutaneous melanoma can develop in-transit metastases (ITM), most often localized to limbs. For patients with uveal melanoma that develop metastatic disease, the overall majority develop isolated liver metastases. For these types of metastases, regional cancer therapies have evolved as effective treatments. Isolated limb perfusion (ILP), isolated limb infusion (ILI), isolated hepatic perfusion (IHP) and percutaneous hepatic perfusion (PHP) achieve a high local concentration of chemotherapy with minimal systemic exposure. This review discusses the mechanism and available literature on locoregional treatment modalities in the era of modern immunotherapy.
引用
收藏
页码:447 / 456
页数:10
相关论文
共 92 条
  • [1] Uveal Melanoma Exosomes Induce a Prometastatic Microenvironment through Macrophage Migration Inhibitory Factor
    Ambrosini, Grazia
    Rai, Alex J.
    Carvajal, Richard D.
    Schwartz, Gary K.
    [J]. MOLECULAR CANCER RESEARCH, 2022, 20 (04) : 661 - 669
  • [2] Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
    Ambrosini, Grazia
    Pratilas, Christine A.
    Qin, Li-Xuan
    Tadi, Madhavi
    Surriga, Oliver
    Carvajal, Richard D.
    Schwartz, Gary K.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (13) : 3552 - 3561
  • [3] Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III- IV melanoma
    Andtbacka, Robert H., I
    Collichio, Frances
    Harrington, Kevin J.
    Middleton, Mark R.
    Downey, Gerald
    Ohrling, Katarina
    Kaufman, Howard L.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] [Anonymous], 2013, J Clin Oncol, DOI DOI 10.1200/JCO.2013.31.15_SUPPL.9031
  • [5] [Anonymous], 2015, COMP DABRAFENIB TRAM
  • [6] Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade
    Ariyan, Charlotte E.
    Brady, Mary Sue
    Siegelbaum, Robert H.
    Hu, Jian
    Bello, Danielle M.
    Rand, Jamie
    Fisher, Charles
    Lefkowitz, Robert A.
    Panageas, Kathleen S.
    Pulitzer, Melissa
    Vignali, Marissa
    Emerson, Ryan
    Tipton, Christopher
    Robins, Harlan
    Merghoub, Taha
    Yuan, Jianda
    Jungbluth, Achim
    Blando, Jorge
    Sharma, Padmanee
    Rudensky, Alexander Y.
    Wolchok, Jedd D.
    Allison, James P.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2018, 6 (02) : 189 - 200
  • [7] Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040
    Arnold, Melina
    Singh, Deependra
    Laversanne, Mathieu
    Vignat, Jerome
    Vaccarella, Salvatore
    Meheus, Filip
    Cust, Anne E.
    de Vries, Esther
    Whiteman, David C.
    Bray, Freddie
    [J]. JAMA DERMATOLOGY, 2022, 158 (05) : 495 - 503
  • [8] AUSMAN R K, 1960, Surg Forum, V10, P77
  • [9] AUST JB, 1960, CANCER CHEMOTH REP, P23
  • [10] Bagge O, 2023, J CLIN ONCOL